Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.91 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.91 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | CYBB | P04839 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL27701439 | 0.98 | OPRM1 (0.88) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13800804 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL13813558 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL6745239 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1561081 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL1994014 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL10069639 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22163723 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL22058352 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 | |
| Oxycodone SCHEMBL2737 | 0.95 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915285-B2 | Method for treating drug and behavioral addictions | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-03-29 | — | — | US | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117425652-A | Novel salts and crystals | 细胞内治疗公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116964190-A | Method for increasing yields of morphinan alkaloids and derivatives | 安思雅公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022109194-A9 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230104286-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220162656-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2022-05-26 | — | — | US | disclosed |
| WO-2019028390-A1 | ENGINEERED BENZYLISOQUINOLINE ALKALOID EPIMERASES AND METHODS OF PRODUCING BENZYLISOQUINOLINE ALKALOIDS | ANTHEIA, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-8067597-B2 | Synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs | MALLINCKRODT LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067243-B2 | Methods and systems for analyzing medication levels in a sample | OREGON MEDICAL LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1893616-B1 | A SYNTHETIC ROUTE TO 14-HYDROXYL OPIATES THROUGH 1-HALO-THEBAINE OR ANALOGS | MALLINCKRODT INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100051801-A1 | METHODS AND SYSTEMS FOR ANALYZING MEDICATION LEVELS IN A SAMPLE | OREGON MEDICAL LABORATORIES | 2010-03-04 | — | — | US | disclosed |
| US-20080207906-A1 | Synthetic Route to 14-Hydroxyl Opiates Through 1-Halo-Thebaine or Analogs | MALLINCKRODT ENTERPRISES LLC | 2008-08-28 | — | — | US | disclosed |
| EP-1893616-A2 | A NEW SYNTHETIC ROUTE TO 14-HYDROXYL OPIATES THROUGH 1-HALO-THEBAINE OR ANALOGS | MALLINCKRODT, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1855657-A2 | DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE | EURO-CELTIQUE S.A. (LU) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006138020-A2 | A SYNTHETIC ROUTE TO 14-HYDROXYL OPIATES THROUGH 1-HALO-THEBAINE OR ANALOGS | MALLINCKRODT INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006089973-A2 | DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE | EURO-CELTIQUE S.A. (LU) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207906-A1 | Synthetic Route to 14-Hydroxyl Opiates Through 1-Halo-Thebaine or Analogs | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.